Screener
Prime Medicine PRME Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
| (in thousands, except share and per share amounts) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total other income, net | 1,176 | 786 | 2,708 | 1,288 |
| Net loss attributable to common stockholders | $(42,109) | $(52,591) | $(91,231) | $(104,481) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.24) | $(0.41) | $(0.51) | $(0.81) |
| Weighted-average common shares outstanding, basic and diluted | 177,224,892 | 129,185,918 | 177,160,914 | 128,439,349 |
| Comprehensive loss: | ||||
| Net loss | $(42,109) | $(52,591) | $(91,231) | $(104,481) |
| Change in unrealized (loss) income on investments, net of tax | (8) | 5 | (91) | (11) |
| Comprehensive loss | $(42,117) | $(52,586) | $(91,322) | $(104,492) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Prime Medicine's net income?
- Prime Medicine (PRME) reported net income of -$42.11M in Q2 2026.
- How has Prime Medicine's net income changed year-over-year?
- Prime Medicine's net income increased by 19.9% year-over-year, from -$52.59M to -$42.11M.
- What is the long-term trend for Prime Medicine's net income?
- Over 4 years (2021 to 2025), Prime Medicine's net income has grown at a 5.0% compound annual growth rate (CAGR), from -$165.37M to -$201.14M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Prime Medicine's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude